Zypitamag (pitavastatin magnesium) NDC 25208-202

NDC codes

FDA NDC Directory

Product NDC (as listed)25208-202Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25208-0202Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
25208-202-09	25208020209	90 TABLET, FILM COATED in 1 BOTTLE (25208-202-09)Marketed from Mar 9, 2018
25208-202-15	25208020215	500 TABLET, FILM COATED in 1 BOTTLE (25208-202-15)Marketed from Mar 9, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zypitamag
Generic name (nonproprietary): pitavastatin magnesium
Active ingredients: Pitavastatin — 4 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Medicure International Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 208379
Marketing start: Mar 9, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Hydroxymethylglutaryl-CoA Reductase Inhibitors (Mechanism)
Identifiers: Product ID 25208-202_d39ef44a-4e4d-459d-86bd-79394202e3ecSPL ID d39ef44a-4e4d-459d-86bd-79394202e3ecSPL set ID c8c50e03-5cb8-43f4-bdef-8edd12f1945fRxCUI 2001262, 2001264, 2001266, 2001268UNII M5681Q5F9PUPC 0325208202156, 0325208201159
Pharmacologic class: HMG-CoA Reductase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N425208020209 followed by a unit qualifier and the quantity

Package 25208-0202-09. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 3, 2025.

Indications (excerpt from the label)

ZYPITAMAG is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. Pediatric use information is approved for Kowa Co Ltd LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd marketing exclusivity rights, this drug product is not labeled with that information. ZYPITAMAG is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 208379

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 208379
Product	Strength	Form · route	Labeler	Product NDC
Zypitamagpitavastatin magnesium	Pitavastatin 2 mg/1	Tablet, Film coatedOral	Medicure International Inc	25208-201
Zypitamagpitavastatin magnesium	Pitavastatin 2 mg/1	Tablet, Film coatedOral	Zydus Lifesciences Limited	70771-1117
Zypitamagpitavastatin magnesium	Pitavastatin 4 mg/1	Tablet, Film coatedOral	Zydus Lifesciences Limited	70771-1118